Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Corporate & Regulatory

Russian court practice on foreign shareholder rights under Russian corporate law in the pharmaceuticals sector: 2027 update

Stanislav Lastovsky · July 2026 · 8 min read

Russian courts refined foreign shareholder governance rights in pharmaceutical companies in 2027. Key changes for in-house counsel. Make an enquiry.

Following a sequence of decisions handed down by Russian commercial courts in the first quarter of 2027, the procedural and substantive position of foreign shareholders in Russian pharmaceutical companies has shifted in ways that in-house counsel for multinational pharmaceutical groups should now address directly. The changes are not legislative: no new statute has come into force. What has changed is the interpretive weight that courts are placing on existing corporate legislation when applied to the pharmaceutical sector – a regulated industry subject to licensing constraints that courts have increasingly treated as bearing on governance rights, not only operational permissions.

§ I. What changed: the interpretive shift in Russian courts

The principal development is a movement in court reasoning that treats pharmaceutical licensing requirements as relevant to the scope of shareholder participation in governance decisions. Under Russian corporate legislation applicable to limited liability companies and joint-stock companies, shareholders and participants hold established rights to information, to participation in general meetings, and to challenge decisions taken in breach of procedure. These rights have not been amended. What courts have done in recent decisions is assess the exercise of those rights against the backdrop of sector-specific regulatory obligations – reasoning, in effect, that governance actions taken by or at the instigation of a foreign shareholder that create regulatory risk for the company's pharmaceutical licence may be subject to additional scrutiny when challenged by Russian co-participants.

The practical consequence is a narrowing of the circumstances in which a foreign minority shareholder can obtain judicial relief for exclusion from governance processes, where the Russian majority can point to a plausible regulatory justification. Courts have not endorsed blanket exclusion. The threshold argument – that the foreign participant's conduct, or the consequence of the governance decision in question, would imperil the company's pharmaceutical operating licence – requires substantiation. But in the matters reviewed, that substantiation has in practice been provided at a relatively low evidential threshold.

A secondary development concerns information rights. Foreign shareholders in pharmaceutical companies have encountered increased resistance, affirmed in some first-instance decisions, to requests for access to documents containing formulation data, supplier chain records, and regulatory filings that straddle the boundary between corporate information and confidential commercial data protected under pharmaceutical legislation. The precise contours of this boundary remain unsettled; the higher commercial courts have not yet produced a unified circuit-level ruling.

For in-house counsel at pharmaceutical groups assessing how these developments affect existing Russian subsidiary governance arrangements, an early review of shareholder agreements and the corporate documents of the Russian entity is the appropriate first step. Make an enquiry: info@vetrovpartners.com |

§ II. Who is affected, and why does this matter for your Russian subsidiary?

The entities most directly affected are foreign-owned or foreign-co-owned Russian limited liability companies and joint-stock companies operating under pharmaceutical manufacturing or distribution licences issued by the relevant Russian regulatory authority. This includes subsidiaries of multinational originators, joint ventures with Russian partners in generic manufacturing, and distribution entities that hold their own licensing permissions.

The relevance varies by ownership structure. A wholly-owned foreign subsidiary in Russia – where there is no Russian co-participant – is unlikely to encounter these developments in practice: the governance conflict scenario that has produced the case line requires a Russian majority or substantial minority participant to raise the regulatory-risk argument. The more exposed structures are joint ventures, co-investments, and privatisation-era arrangements in which a foreign group holds a minority or equal share alongside a Russian strategic partner or state-affiliated participant.

For in-house counsel managing these structures, the immediate concern is less about catastrophic outcome and more about procedural attrition: governance decisions that the foreign shareholder reasonably expects to pass may be challenged, delayed, or reversed on regulatory-interest grounds that are difficult to contest quickly. The secondary concern is information asymmetry – reduced access to the operational data that an international parent requires for group consolidation, regulatory reporting, and transfer-pricing documentation.

The sector dimension is significant here. Unlike general manufacturing or retail, a pharmaceutical company in Russia operates under a licensing framework that ties commercial viability directly to regulatory standing. That dependency gives the regulatory-risk argument a credibility it would lack in less regulated sectors. For groups whose Russian operations are in FMCG pharmaceuticals, over-the-counter distribution, or localisation arrangements under EAEU requirements, the interaction between corporate governance rights and pharmaceutical regulatory compliance is now a live legal question, not a theoretical one.

"Russian courts have, in a series of 2027 decisions, begun to treat pharmaceutical licensing obligations as a substantive factor in assessing the permissible scope of foreign shareholder governance rights – a development that requires immediate attention from in-house counsel with Russian pharmaceutical assets." — Stanislav Lastovsky, Senior Lawyer, Practice Lead — Restructuring & Insolvency, Vetrov & Partners

For in-house counsel advising pharmaceutical joint ventures or Russian subsidiary boards where these structures are in place, the regulatory-interest argument is now a litigation risk that should be factored into governance documentation and board protocols. For an assessment of your specific structure, make an enquiry: info@vetrovpartners.com |

§ III. What foreign shareholders in Russian pharmaceutical companies should do now

Three areas of action are appropriate for in-house counsel following these developments.

The first is a review of the constitutional documents of the Russian entity – the charter and, where a shareholders' agreement exists, its terms – against the current interpretive environment. Provisions that were drafted to protect foreign shareholder governance rights in standard corporate terms may not have been tested against a pharmaceutical-regulatory-risk defence. Where the charter permits the Russian majority to take governance actions without minority consent on grounds that include regulatory compliance, the scope of that permission should be understood and, where possible, narrowed or clarified by amendment before a dispute arises.

The second area concerns information rights. Groups relying on the Russian subsidiary to provide consolidated financial data, transfer-pricing documentation, and regulatory submission records for group purposes should identify which categories of information now face elevated access resistance, and put in place alternative arrangements – contractual, board-level, or through the audit process – to secure access through channels less vulnerable to the information-right limitation described in § I.

The third area is dispute readiness. In-house counsel should ensure that Russian local counsel have been instructed and that the firm's understanding of the current court position – including the specific circuit courts with jurisdiction over the relevant Russian entity – is current. The decisions described in this update originate predominantly from courts in Moscow and the Central District; the position in Siberian and Ural circuit courts, where pharmaceutical manufacturing facilities are concentrated, is developing and may differ at first instance. The firm's Corporate Governance practice monitors circuit-level developments across the Siberian Federal District on a continuous basis.

For broader context on the procedural rights available to foreign shareholders in Russian companies, see A Practical Guide to Foreign Shareholder Rights in Russia and Foreign Shareholder Rights Under Russian Corporate Law. Groups with parallel concerns about the financial position of the Russian entity should also consult the firm's Restructuring & Insolvency practice page. A full record of relevant matters handled is available at /matters/.

Open questions: what courts have not yet resolved

Two significant interpretive questions remain open. First, whether the regulatory-risk defence available to a Russian majority participant operates differently in a joint-stock company with a supervisory board – where governance rights are more formally structured – than in a limited liability company. The case law to date has arisen primarily in the LLC context. Second, whether the evidential standard for the regulatory-risk argument will be tightened by circuit-level review, or whether the relatively permissive first-instance approach will be affirmed. Both questions are likely to receive appellate attention in the second half of 2027.

Frequently asked questions

Q: What specifically changed in Russian court practice on foreign shareholder rights in the pharmaceuticals sector in 2027?

A: No new legislation was enacted. The change is interpretive: Russian commercial courts have, in a line of decisions from early 2027, treated pharmaceutical licensing obligations as a material factor when assessing whether a foreign minority shareholder's governance rights were legitimately restricted by the Russian majority. Courts have accepted, at a relatively low evidential threshold, arguments that a governance action requested or initiated by a foreign participant carried regulatory risk for the company's pharmaceutical licence. The scope of this defence remains unsettled at circuit level, but the first-instance trend is consistent.

Q: Which foreign shareholders are most affected by these developments, and how?

A: The companies most exposed are foreign shareholders in Russian pharmaceutical joint ventures or co-investment structures where a Russian strategic or state-affiliated partner holds a majority or substantial minority. Wholly-owned foreign subsidiaries with no Russian co-participant are unlikely to be directly affected. The practical risks are twofold: governance attrition – difficulty in pushing through decisions the foreign shareholder considers routine – and information asymmetry, as courts have in some instances affirmed restrictions on access to documents that straddle corporate information and protected pharmaceutical data. Groups whose Russian structures involve EAEU localisation arrangements face a particular interface between pharmaceutical regulatory compliance and corporate governance rights.

Q: What should in-house counsel do in response to these court decisions?

A: Three immediate steps are appropriate: review the charter and shareholders' agreement of the Russian entity with current interpretive guidance in mind; assess which categories of corporate information may now face access resistance and establish alternative mechanisms for obtaining that data; and confirm that local Russian counsel with knowledge of the relevant circuit courts are in place. Groups with complex or contested governance arrangements in Russian pharmaceutical subsidiaries should not treat this as a deferred compliance matter – the timeline for appealing adverse first-instance decisions in the Russian commercial court system is short.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry